Please login to the form below

Not currently logged in
Email:
Password:

Biogen's Alzheimer's drug Aduhelm

This page shows the latest Biogen's Alzheimer's drug Aduhelm news and features for those working in and with pharma, biotech and healthcare.

Biogen retracts EMA application for Alzheimer's drug Aduhelm

Biogen retracts EMA application for Alzheimer's drug Aduhelm

Following regulatory blocks and rejections late last year, Biogen has decided to withdraw its application for its Alzheimer's drug Aduhelm (aducanumab) in Europe. ... said the results ‘did not show overall that Aduhelm was effective at treating adults

Latest news

  • Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US Biogens Alzheimers treatment Aduhelm limited to clinical trial participants in the US

    The drug was given clearance on the strict condition that Biogen conducted an additional trial to confirm the benefits of using Aduhelm. ... Following a thorough analysis, CMS discovered that although Aduhelm had the potential to help patients with

  • Biogen investigating death linked to Aduhelm Biogen investigating death linked to Aduhelm

    The death of a 75-year-old patient taking Biogen’s Aduhelm has raised yet more questions around the recently approved Alzheimer’s therapy. ... Yet, the arrival of a potential treatment, Biogen’s Aduhelm (aducanumab), has not perhaps been welcomed

  • Rocky start for Biogen’s Alzheimer’s drug Aduhelm Rocky start for Biogens Alzheimers drug Aduhelm

    Controversial Alzheimer’s treatment Aduhelm is struggling to realise its potential, with only 100 patients receiving the therapy so far in the US. ... Embattled Biogen has encountered yet more setbacks in the roll-out of its Alzheimer’s disease

  • Embattled Biogen talks up Aduhelm Embattled Biogen talks up Aduhelm

    Biogen CEO admitted the company was experiencing “near-term challenges” after the controversial approval of Alzheimer’s drug, Aduhelm. ... For Biogen’s Aduhelm (aducanumab), however, the road has been far from smooth, with intense criticism of

  • Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm

    Congress demands more information from the FDA on its controversial approval of Biogen’s Alzheimer’s drug and its dealings with the company. ... After the unexpected departure of its vaccines heads, Congress is now demanding more information on the

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....